3-methoxy-2,6-dimethylbenzaldehyde | 179554-12-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-methoxy-2,6-dimethylbenzaldehyde
• CAS: 179554-12-2
• 化学式: C₁₀H₁₂O₂
• 分子量: 164.204
• InChiKey: ZQUPZNYHVCUOAZ-UHFFFAOYSA-N

物化性质

• 沸点：
  266.0±35.0 °C(Predicted)
• 密度：
  1.041±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-methoxy-2,6-dimethylbenzaldehyde 在 lithium aluminium tetrahydride 、 三溴化磷 作用下， 以 乙醚 为溶剂， 生成 2-(bromomethyl)-4-methoxy-1,3-dimethylbenzene
  参考文献：
  名称：

  Synthesis of (±)-14-epi-hydroxydolasta-1(15),7,9-triene and (±)-7-epi-acetoxy-14-epi-hydroxydolasta-1(15),8-diene^*Taken in part from the Ph.D. dissertation of Jianhua Yu, University of Georgia, Athens, Georgia, USA, 2009.

  摘要：

  1,3-二甲基-2-硝基苯被转化为关键的分子内Friedel-Crafts中间体24，经过十个步骤。用TiCl₄处理24产生三环烯酮25，收率为61%–75%，具有两个角甲基的必需的反式关系和多个dolastane二萜的显著特征。通过X射线晶体学分析验证了烯酮25的结构。环化产物25促进了(±)-14-epi-hydroxydolasta-1(15),7,9-三烯和(±)-7-epi-acetoxy-14-epi-hydroxydolasta-1(15),8-二烯的简便合成，这些在本文中有详细描述。

  DOI：

  10.1139/v11-116
• 作为产物：
  描述：

  3-methoxy-2,6-dimethylaniline 在 硫酸 、 叔丁基锂 作用下， 以 四氢呋喃 、 水 、 乙腈 、 正戊烷 为溶剂， 反应 3.58h， 生成 3-methoxy-2,6-dimethylbenzaldehyde
  参考文献：
  名称：

  COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE

  摘要：

  Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.

  公开号：

  US20230122909A1

文献信息

• COMPOUNDS AND METHOD FOR PKMYT1 INHIBITION
  申请人：ENGINE BIOSCIENCES PTE. LTD.

  公开号：WO2023249563A1

  公开（公告）日：2023-12-28

  The disclosure provides for compounds and methods for inhibiting protein kinase, membrane associate tyrosine/threonine 1 (PKMYT1).

  本公开提供了抑制膜联酪氨酸/苏氨酸蛋白激酶 1（PKMYT1）的化合物和方法。
• IMIDAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS IN PARTICULAR EGF-R TYROSINE KINASE
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0797575A1

  公开（公告）日：1997-10-01
• [EN] IMIDAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS IN PARTICULAR EGF-R TYROSINE KINASE<br/>[FR] DERIVES IMIDAZOLES UTILISES COMME INHIBITEURS DE LA PROTEINE KINASE, NOTAMMENT DE LA TYROSINE KINASE DU RECEPTEUR DU FACTEUR DE CROISSANCE DE L'EPIDERME (EGF-R)
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：WO1996018626A1

  公开（公告）日：1996-06-20

  (EN) Imidazole derivatives of general formula (I), wherein R1-R8 each independently signify hydrogen, lower-alkyl, substituted lower alkyl, lower-alkenyl, lower-alkoxy, substituted lower alkoxy, lower-alkoxycarbonyl, halogen, hydroxy, amino, mono- or di(lower-alkyl)amino or nitro, and pharmaceutically usable salts thereof are protein kinase inhibitors and can be used as medicaments, e.g. for the control of hyperproliferative disorders such as atherosclerosis, psoriasis and tumors as well as of alopecia.(FR) Dérivés imidazoles de la formule générale (I) et leurs sels acceptables sur le plan pharmacologique. Dans cette formule, R1-R8 représentent chacun indépendamment hydrogène, alkyle inférieur, alkyle inférieur substitué, alcényle inférieur, alcoxy inférieur, alcoxy inférieur substitué, alcoxycarbonyle inférieur, halogène, hydroxy, amino, mono ou di(alkyle inférieur)amino ou nitro. Ces dérivés sont des inhibiteurs des protéines kinases et on peut les utiliser en tant que médicaments, par exemple pour lutter contre les désordres excessivement prolifératifs tels que l'athérosclérose, le psoriasis et les tumeurs, de même que l'alopécie.
• Synthesis of (±)-14-<i>epi</i>-hydroxydolasta-1(15),7,9-triene and (±)-7-<i>epi</i>-acetoxy-14-<i>epi</i>-hydroxydolasta-1(15),8-diene^*Taken in part from the Ph.D. dissertation of Jianhua Yu, University of Georgia, Athens, Georgia, USA, 2009.
  作者：George Majetich、Jianhua Yu

  DOI：10.1139/v11-116

  日期：2012.1

  1,3-Dimethyl-2-nitrobenzene was converted to the key intramolecular Friedel–Crafts intermediate 24 in ten steps. Treatment of 24 with TiCl₄ produced tricyclic enone 25 in 61%–75% yield, having the requisite trans relationship of the two angular methyl groups and many of the salient features of the dolastane diterpenes. The structure of enone 25 was verified by X-ray crystallography analysis. Cyclization product 25 permitted the facile synthesis of (±)-14-epi-hydroxydolasta-1(15),7,9-triene and (±)-7-epi-acetoxy-14-epi-hydroxydolasta-1(15),8-diene, which are detailed in this article.

  1,3-二甲基-2-硝基苯被转化为关键的分子内Friedel-Crafts中间体24，经过十个步骤。用TiCl₄处理24产生三环烯酮25，收率为61%–75%，具有两个角甲基的必需的反式关系和多个dolastane二萜的显著特征。通过X射线晶体学分析验证了烯酮25的结构。环化产物25促进了(±)-14-epi-hydroxydolasta-1(15),7,9-三烯和(±)-7-epi-acetoxy-14-epi-hydroxydolasta-1(15),8-二烯的简便合成，这些在本文中有详细描述。
• COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE
  申请人：Repare Therapeutics Inc.

  公开号：US20230122909A1

  公开（公告）日：2023-04-20

  Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.